AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11889391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (50 microg/100 mL, two puffs for each nostril once daily)
Number of subjects: 60
Study 11889391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.05%, one puff for each nostril three times daily)
Number of subjects: 60
Study 11889391 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Sodium chloride (NaCl, buffered to pH 6.5‐7, given three times daily)
Number of subjects: 60
Study 11889391 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium chloride (NaCl, 10-mL solutions for nasal irrigations three times daily)
Number of subjects: 60
Study 11889391 — intervention group
Group type: COMPARATOR
Intervention: No topical treatment (control group)
Number of subjects: 60
Study 9698957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive pressure ventilation (CPPV) plus surfactant (50 mg/kg body weight)
Number of subjects: 20
Study 9698957 — intervention group
Group type: COMPARATOR
Intervention: CPPV only
Number of subjects: 20
Study 7596744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns presented at identical locations (ILs) on the skin
Number of subjects: 0
Study 7596744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns presented at varying distances between locations
Number of subjects: 0
Study 7596744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns presented to corresponding points on separate fingerpads
Number of subjects: 0
Study 7596744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns presented to noncorresponding points on separate fingers
Number of subjects: 0
Study 2141487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 82
Study 2141487 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 82
Study 835326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy
Number of subjects: 183
Study 835326 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 183
Study 835326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 183
Study 30999596 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Replacement (MRP; 70% fat) consumed once daily for eight weeks
Number of subjects: 42
Study 30999596 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42
Study 26609965 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact aerobics (HIA)
Number of subjects: 32
Study 26609965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact aerobics combined with strength training (LIAS)
Number of subjects: 32
Study 26609965 — intervention group
Group type: COMPARATOR
Intervention: Both groups (HIA and LIAS)
Number of subjects: 32
Study 26560326 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 0
Study 23912917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 558
Study 23912917 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 558
Study 23912917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stents
Number of subjects: 558
Study 23912917 — intervention group
Group type: EXPERIMENTAL
Intervention: Other medications
Number of subjects: 558
Study 22121936 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced multimedia version of CBT-I
Number of subjects: 106
Study 22121936 — intervention group
Group type: EXPERIMENTAL
Intervention: Book version of CBT-I
Number of subjects: 106
Study 22121936 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no significant medical condition)
Number of subjects: 106
Study 19230048 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: rabeprazole 10 mg + amoxicillin 1 g + furazolidone 100 mg + bismuth subcitrate 220 mg, twice daily for 1 week
Number of subjects: 60
Study 19230048 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: same regimen as Group A but for 2 weeks
Number of subjects: 60
Study 19230048 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: same regimen as Group B, but furazolidone was replaced by furazolidone 100 mg three times daily
Number of subjects: 60
Study 19230048 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 17784949 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g lactulose daily for 4 months
Number of subjects: 31
Study 17784949 — intervention group
Group type: COMPARATOR
Intervention: Standard medication alone
Number of subjects: 31
Study 15491688 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5F ureteroscope
Number of subjects: 100
Study 15491688 — intervention group
Group type: COMPARATOR
Intervention: 10F ureteroscope
Number of subjects: 100
Study 11838823 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive haloperidol
Number of subjects: 5
Study 11838823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 5
Study 9494310 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Infant Pain Scale (MIPS)
Number of subjects: 40
Study 9494310 — intervention group
Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 40
Study 7768135 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tilt table test (BTTT)
Number of subjects: 144
Study 7768135 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistage isoproterenol tilt table test (MITTT)
Number of subjects: 144
Study 7768135 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stage isoproterenol tilt table test (SITTT)
Number of subjects: 144
Study 7768135 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 144
Study 3263812 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (mean dosage 74 (SD 4) micrograms/kg/min for 0‐20 minutes and 51 (SD 7) micrograms/kg/min for 20‐40 minutes)
Number of subjects: 50
Study 3263812 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (35 micrograms/kg + 2.54 (SD 0.2) micrograms/kg/min for 0‐20 minutes and 1.35 (SD 0.2) micrograms/kg/min for 20‐40 minutes)
Number of subjects: 50
Study 3263812 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 50
Study 1233261 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐356 (525 mg)
Number of subjects: 32
Study 1233261 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐356 (2100 or 1050 mg)
Number of subjects: 32
Study 1233261 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐356 (400 mg probenecid coadministered with 700 mg pivampicillin)
Number of subjects: 32
Study 1233261 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin (350 mg)
Number of subjects: 32
Study 30191365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Number of subjects: 0
Study 30191365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 30191365 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 28728559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and therapeutic adjustments
Number of subjects: 0
Study 28728559 — intervention group
Group type: COMPARATOR
Intervention: Current American Diabetes Association (ADA) usual recommendations for nutritional and pharmacological adjustments for exercise
Number of subjects: 0
Study 26055239 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min daily exercise intervention (standing, upright exercise regimen)
Number of subjects: 10
Study 26055239 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 10
Study 23417198 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (two pieces of sugarless gum for 30 min in the morning, noon, evening, and bedtime until the first flatus, along with conventional postoperative feeding protocol)
Number of subjects: 50
Study 23417198 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 50
Study 23417198 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeding protocol without gum chewing
Number of subjects: 50
Study 23417198 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing and Conventional feeding protocol
Number of subjects: 50
Study 21394549 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week progressive resistance training
Number of subjects: 74
Study 18719924 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFB)
Number of subjects: 48
Study 18719924 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A (BTX-A) injection
Number of subjects: 48
Study 18719924 — intervention group
Group type: COMPARATOR
Intervention: Both BFB and BTX-A
Number of subjects: 48
Study 17938015 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 0
Study 15061154 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (level 1)
Number of subjects: 4000
Study 15061154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, Bupropion, Venlafaxine, Cognitive Therapy (level 2 switch options)
Number of subjects: 4000
Study 15061154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (level 2 augment option)
Number of subjects: 4000
Study 15061154 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine, Nortriptyline (level 3 switch options)
Number of subjects: 4000
Study 15061154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium, Thyroid Hormone (level 3 augment options)
Number of subjects: 4000
Study 15061154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine, Combination of Mirtazapine and Venlafaxine (level 4 switch options)
Number of subjects: 4000
Study 11565941 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Practice
Number of subjects: 60
Study 11565941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Mental and Physical Practice
Number of subjects: 60
Study 11565941 — intervention group
Group type: COMPARATOR
Intervention: No Practice
Number of subjects: 60
Study 11565941 — intervention group
Group type: COMPARATOR
Intervention: Mental Practice
Number of subjects: 60
Study 9354195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 24
Study 9354195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 24
Study 9354195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8249560 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O group (isoflurane in nitrous oxide and 30% oxygen)
Number of subjects: 36
Study 8249560 — intervention group
Group type: COMPARATOR
Intervention: Air group (isoflurane in air and 30% oxygen)
Number of subjects: 36
Study 3307670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 284
Study 3307670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 29582084 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 1089
Study 29582084 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 1089
Study 26621110 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin (24 h further fixation)
Number of subjects: 200
Study 26621110 — intervention group
Group type: COMPARATOR
Intervention: GEWF immersion
Number of subjects: 200
Study 26621110 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study 23657087 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery of colonic transit (geometric center of radioactivity ≥2 on day 3)
Number of subjects: 84
Study 23657087 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcome measure of tolerance of solid food and having had defecation (SF + D)
Number of subjects: 84
Study 23657087 — intervention group
Group type: EXPERIMENTAL
Intervention: SF + D
Number of subjects: 84
Study 23657087 — intervention group
Group type: COMPARATOR
Intervention: Time to first flatus
Number of subjects: 84
Study 23780807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medications (including statins)
Number of subjects: 0
Study 23780807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medications (after 2002)
Number of subjects: 0
Study 23780807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medications (trend after 2002)
Number of subjects: 0
Study 20519680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidal stimulation
Number of subjects: 299
Study 20519680 — intervention group
Group type: COMPARATOR
Intervention: Subthalamic stimulation
Number of subjects: 299
Study 20467622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronic acid
Number of subjects: 72
Study 20467622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrier)
Number of subjects: 72
Study 16007328 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate therapy with calcium + vitamin D
Number of subjects: 0
Study 16007328 — intervention group
Group type: COMPARATOR
Intervention: Calcium + vitamin D alone (control group)
Number of subjects: 0
Study 12824258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (40 microg/kg per minute, 30 minutes per infusion step)
Number of subjects: 12
Study 12861835 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine and papaverine (Group 1)
Number of subjects: 56
Study 12861835 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine, papaverine, and ligustrazin hydrochloride (Group 2)
Number of subjects: 56
Study 10468312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride 100 mg
Number of subjects: 12
Study 10468312 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 1 mg
Number of subjects: 12
Study 10468312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8647479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-induced hypertension (PIH)
Number of subjects: 32
Study 8647479 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy (Control)
Number of subjects: 32
Study 1369845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation with K-wires of the opposite hip as prophylaxis against slipping
Number of subjects: 47
Study 324417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative antibiotic wound lavage
Number of subjects: 434
Study 324417 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 434
Study 324417 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic solution irrigation
Number of subjects: 434
Study 324417 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic wound lavage
Number of subjects: 434
Study 324417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative wound lavage
Number of subjects: 434
Study 31773882 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I foam dressing
Number of subjects: 71
Study 31773882 — intervention group
Group type: COMPARATOR
Intervention: Foam dressing (Medifoam)
Number of subjects: 71
Study 28249808 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 30
Study 28249808 — intervention group
Group type: COMPARATOR
Intervention: Control (suture only)
Number of subjects: 30
Study 25482832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg orally daily for 24 weeks
Number of subjects: 50
Study 25482832 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 50
Study 25482832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 50
Study 25482832 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic responders
Number of subjects: 50
Study 23332288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2)
Number of subjects: 130
Study 23332288 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2) plus carboplatin (AUC 6)
Number of subjects: 130
Study 20154505 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased knee extension strength
Number of subjects: 417
Study 17888680 — intervention group
Group type: EXPERIMENTAL
Intervention: Central posteroanterior (PA) mobilisation to L3 for 2 minutes
Number of subjects: 36
Study 17888680 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 36
Study 17888680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no active intervention)
Number of subjects: 36
Study 16776916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone alone
Number of subjects: 181
Study 16776916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus losartan
Number of subjects: 181
Study 16776916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus perindopril
Number of subjects: 181
Study 15600384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 317
Study 15600384 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 317
Study 15600384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 317
Study 11775652 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 23
Study 11775652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11775652 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 9709270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group invited to screening
Number of subjects: 7
Study 9709270 — intervention group
Group type: COMPARATOR
Intervention: Control group not invited to screening
Number of subjects: 7
Study 8020529 — intervention group
Group type: EXPERIMENTAL
Intervention: Asiatic acid (12 mg)
Number of subjects: 12
Study 8020529 — intervention group
Group type: COMPARATOR
Intervention: Asiaticoside (24 mg)
Number of subjects: 12
Study 29271805 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Eye Care (PEC)
Number of subjects: 233
Study 29271805 — intervention group
Group type: COMPARATOR
Intervention: Tertiary Specialist Outpatient Clinic (SOC)
Number of subjects: 233
Study 27580837 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 344
Study 27580837 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy-led best conservative care
Number of subjects: 344
Study 23300047 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advertisements
Number of subjects: 227
Study 23300047 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements attributed to a nonprofit source
Number of subjects: 227
Study 23300047 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial advertisements rated as credible
Number of subjects: 227
Study 23300047 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance condition advertisements attributed to a nonprofit source
Number of subjects: 227
Study 22182435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafts mixed with PRP
Number of subjects: 60
Study 22182435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative laser
Number of subjects: 60
Study 22182435 — intervention group
Group type: COMPARATOR
Intervention: Fat grafts mixed with PRP plus nonablative laser resurfacing
Number of subjects: 60
Study 20225911 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention to improve quality of life among patients with CHF
Number of subjects: 458
Study 20225911 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 458
Study 18279476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 22 mg 0.8 ml(‐1)
Number of subjects: 22
Study 18279476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18279476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 22
Study 16006455 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy first (DLSF) group
Number of subjects: 154
Study 16006455 — intervention group
Group type: COMPARATOR
Intervention: IUI first (IUIF) group
Number of subjects: 154
Study 12469157 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(6) units of macrophage colony-stimulating factor (low dose group)
Number of subjects: 214
Study 12469157 — intervention group
Group type: EXPERIMENTAL
Intervention: 8x10(6) units of macrophage colony-stimulating factor (high dose group)
Number of subjects: 214
Study 10673196 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg
Number of subjects: 349
Study 10673196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 10673196 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 349
Study 10673196 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 microg
Number of subjects: 349
Study 8897961 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine
Number of subjects: 15
Study 8897961 — intervention group
Group type: EXPERIMENTAL
Intervention: dopamine
Number of subjects: 15
Study 1815717 — intervention group
Group type: EXPERIMENTAL
Intervention: Prema Compound
Number of subjects: 21
Study 1815717 — intervention group
Group type: COMPARATOR
Intervention: 12-fluted bur
Number of subjects: 21
Study 6511154 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgenic steroids (average 45 mg/day) during an 8-week strength training period
Number of subjects: 7
Study 30663859 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Observation of Social Communication Change (BOSCC) during home snack routines
Number of subjects: 0
Study 30663859 — intervention group
Group type: COMPARATOR
Intervention: Brief Observation of Social Communication Change (BOSCC) during play routines
Number of subjects: 0
Study 28027010 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-for-mood intervention
Number of subjects: 152
Study 28027010 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise-for-fitness intervention
Number of subjects: 152
Study 28027010 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 152
Study 27215279 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg recombinant HepB vaccine
Number of subjects: 0
Study 27215279 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg recombinant HepB vaccine
Number of subjects: 0
Study 27215279 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg recombinant HepB vaccine (adults)
Number of subjects: 0